Objective：To investigate the therapeutic effect of Mucosta on chronic erosive gastritis for 8 weeks period. Methods：This study enrolled 60 patients with CEG diagnosed by gastroscopy. After 8 weeks of therapy, the changes of symptoms were observed, and the level of PGE2 and MDA were examined. Results：Fifty-six patients with CEG completed 8 weeks of treatment. In the study group and the control group, symptom scores were significantly decreased（P ＜ 0.05）, but there were no significant difference between two groups. A better mucosa restoration on gland density and morphology were observed in the study group（P ＜ 0.05）at the end of 8 weeks. In both groups, the concentration of PGE2 increased significantly and MDA decreased more than before（P ＜ 0.05）, and there was significant difference between the study group and the control group in 8 weeks. Conclusion：The gastric protective drug Mucosta can better relieve the symptoms of the patients with CEG, healing the erosive lesion in the stomach, increasing the level of PGE2 and decreasing the level of MDA. Mucosta is an effective drug for CEG.